A carregar...
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study
An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to identify factors that may have contributed to the favo...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7876889/ https://ncbi.nlm.nih.gov/pubmed/33560384 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002378 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|